Atlas Trials

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Clinical trial NCT01906385 · RECRUITING

Trial details

NCT number
NCT01906385
Sponsor
Plus Therapeutics
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glioma
Start date
2015-06-03
Primary completion
2025-12-01
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.